Loading…

Protective Immunity in Mice Immunized With P. vivax MSP1 19 -Based Formulations and Challenged With P. berghei Expressing Pv MSP1 19

The lack of continuous cultures has been an obstacle delaying pre-clinical testing of vaccine formulations based on known antigens. In this study, we generated a model to test available formulations based on the MSP1 antigen. The strains ANKA and NK65 were modified to express MSP1 instead of the end...

Full description

Saved in:

Bibliographic Details
Published in:	Frontiers in immunology 2020, Vol.11, p.28
Main Authors:	Dobrescu, Irina, de Camargo, Tarsila Mendes, Gimenez, Alba Marina, Murillo, Oscar, Amorim, Kelly Nazaré da Silva, Marinho, Claudio Romero Farias, Soares, Irene Silva, Boscardin, Silvia Beatriz, Bargieri, Daniel Youssef
Format:	Article
Language:	English
Subjects:	Animals Antibodies, Protozoan - immunology Antigens, Protozoan - immunology Female Immunogenicity, Vaccine Malaria Vaccines - immunology Malaria, Vivax - immunology Malaria, Vivax - parasitology Merozoite Surface Protein 1 - immunology Merozoite Surface Protein 1 - metabolism Mice Mice, Inbred BALB C Mice, Inbred C57BL Parasitemia - immunology Plasmids - genetics Plasmodium berghei - genetics Plasmodium berghei - metabolism Plasmodium vivax - immunology Protozoan Proteins - immunology Transfection Treatment Outcome Vaccination
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

cited_by
cites
container_end_page
container_issue
container_start_page	28
container_title	Frontiers in immunology
container_volume	11
creator	Dobrescu, Irina de Camargo, Tarsila Mendes Gimenez, Alba Marina Murillo, Oscar Amorim, Kelly Nazaré da Silva Marinho, Claudio Romero Farias Soares, Irene Silva Boscardin, Silvia Beatriz Bargieri, Daniel Youssef
description	The lack of continuous cultures has been an obstacle delaying pre-clinical testing of vaccine formulations based on known antigens. In this study, we generated a model to test available formulations based on the MSP1 antigen. The strains ANKA and NK65 were modified to express MSP1 instead of the endogenous MSP1 . The hybrid parasites were used to challenge C57BL/6 or BALB/c mice immunized with MSP1 -based vaccine formulations. The MSP1 was correctly expressed in the hybrid mutant lines as confirmed by immunofluorescence using anti- MSP1 monoclonal antibodies and by Western blot. Replacement of the MSP1 by the MSP1 had no impact on asexual growth . High titers of specific antibodies to MSP1 were not sufficient to control initial parasitemia in the immunized mice, but late parasitemia control and a balanced inflammatory process protected these mice from dying, suggesting that an established immune response to MSP1 in this model can help immunity mounted later during infection.
doi_str_mv	10.3389/fimmu.2020.00028
format	article
fullrecord	<record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_32153555</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>32153555</sourcerecordid><originalsourceid>FETCH-pubmed_primary_321535553</originalsourceid><addsrcrecordid>eNqFjk9LwzAYxoMgbujunuT9Aq1J3masV8eGHgYFBY8jW7P2lSYtSVo2z35we7Cwm6cHfs8fHsYeBU8RV_nziaztU8klTznncnXD5mK5zBKUMpuxRQhfI-ZZjojqjs1QCoVKqTn7KXwbzTHSYOBt3HAUL0AOdnScwLcp4ZNiDUUKAw36DLv3QoDIIXnRYTS3rbd9oyO1LoB2Jaxr3TTGVVfFg_FVbQg2586bEMhVUAzT0AO7PekmmMWf3rOn7eZj_Zp0_cGact95stpf9tNt_DfwC2j6Upc</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Protective Immunity in Mice Immunized With P. vivax MSP1 19 -Based Formulations and Challenged With P. berghei Expressing Pv MSP1 19</title><source>PubMed Central</source><creator>Dobrescu, Irina ; de Camargo, Tarsila Mendes ; Gimenez, Alba Marina ; Murillo, Oscar ; Amorim, Kelly Nazaré da Silva ; Marinho, Claudio Romero Farias ; Soares, Irene Silva ; Boscardin, Silvia Beatriz ; Bargieri, Daniel Youssef</creator><creatorcontrib>Dobrescu, Irina ; de Camargo, Tarsila Mendes ; Gimenez, Alba Marina ; Murillo, Oscar ; Amorim, Kelly Nazaré da Silva ; Marinho, Claudio Romero Farias ; Soares, Irene Silva ; Boscardin, Silvia Beatriz ; Bargieri, Daniel Youssef</creatorcontrib><description>The lack of continuous cultures has been an obstacle delaying pre-clinical testing of vaccine formulations based on known antigens. In this study, we generated a model to test available formulations based on the MSP1 antigen. The strains ANKA and NK65 were modified to express MSP1 instead of the endogenous MSP1 . The hybrid parasites were used to challenge C57BL/6 or BALB/c mice immunized with MSP1 -based vaccine formulations. The MSP1 was correctly expressed in the hybrid mutant lines as confirmed by immunofluorescence using anti- MSP1 monoclonal antibodies and by Western blot. Replacement of the MSP1 by the MSP1 had no impact on asexual growth . High titers of specific antibodies to MSP1 were not sufficient to control initial parasitemia in the immunized mice, but late parasitemia control and a balanced inflammatory process protected these mice from dying, suggesting that an established immune response to MSP1 in this model can help immunity mounted later during infection.</description><identifier>EISSN: 1664-3224</identifier><identifier>DOI: 10.3389/fimmu.2020.00028</identifier><identifier>PMID: 32153555</identifier><language>eng</language><publisher>Switzerland</publisher><subject>Animals ; Antibodies, Protozoan - immunology ; Antigens, Protozoan - immunology ; Female ; Immunogenicity, Vaccine ; Malaria Vaccines - immunology ; Malaria, Vivax - immunology ; Malaria, Vivax - parasitology ; Merozoite Surface Protein 1 - immunology ; Merozoite Surface Protein 1 - metabolism ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Parasitemia - immunology ; Plasmids - genetics ; Plasmodium berghei - genetics ; Plasmodium berghei - metabolism ; Plasmodium vivax - immunology ; Protozoan Proteins - immunology ; Transfection ; Treatment Outcome ; Vaccination</subject><ispartof>Frontiers in immunology, 2020, Vol.11, p.28</ispartof><rights>Copyright © 2020 Dobrescu, de Camargo, Gimenez, Murillo, Amorim, Marinho, Soares, Boscardin and Bargieri.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32153555$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dobrescu, Irina</creatorcontrib><creatorcontrib>de Camargo, Tarsila Mendes</creatorcontrib><creatorcontrib>Gimenez, Alba Marina</creatorcontrib><creatorcontrib>Murillo, Oscar</creatorcontrib><creatorcontrib>Amorim, Kelly Nazaré da Silva</creatorcontrib><creatorcontrib>Marinho, Claudio Romero Farias</creatorcontrib><creatorcontrib>Soares, Irene Silva</creatorcontrib><creatorcontrib>Boscardin, Silvia Beatriz</creatorcontrib><creatorcontrib>Bargieri, Daniel Youssef</creatorcontrib><title>Protective Immunity in Mice Immunized With P. vivax MSP1 19 -Based Formulations and Challenged With P. berghei Expressing Pv MSP1 19</title><title>Frontiers in immunology</title><addtitle>Front Immunol</addtitle><description>The lack of continuous cultures has been an obstacle delaying pre-clinical testing of vaccine formulations based on known antigens. In this study, we generated a model to test available formulations based on the MSP1 antigen. The strains ANKA and NK65 were modified to express MSP1 instead of the endogenous MSP1 . The hybrid parasites were used to challenge C57BL/6 or BALB/c mice immunized with MSP1 -based vaccine formulations. The MSP1 was correctly expressed in the hybrid mutant lines as confirmed by immunofluorescence using anti- MSP1 monoclonal antibodies and by Western blot. Replacement of the MSP1 by the MSP1 had no impact on asexual growth . High titers of specific antibodies to MSP1 were not sufficient to control initial parasitemia in the immunized mice, but late parasitemia control and a balanced inflammatory process protected these mice from dying, suggesting that an established immune response to MSP1 in this model can help immunity mounted later during infection.</description><subject>Animals</subject><subject>Antibodies, Protozoan - immunology</subject><subject>Antigens, Protozoan - immunology</subject><subject>Female</subject><subject>Immunogenicity, Vaccine</subject><subject>Malaria Vaccines - immunology</subject><subject>Malaria, Vivax - immunology</subject><subject>Malaria, Vivax - parasitology</subject><subject>Merozoite Surface Protein 1 - immunology</subject><subject>Merozoite Surface Protein 1 - metabolism</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Mice, Inbred C57BL</subject><subject>Parasitemia - immunology</subject><subject>Plasmids - genetics</subject><subject>Plasmodium berghei - genetics</subject><subject>Plasmodium berghei - metabolism</subject><subject>Plasmodium vivax - immunology</subject><subject>Protozoan Proteins - immunology</subject><subject>Transfection</subject><subject>Treatment Outcome</subject><subject>Vaccination</subject><issn>1664-3224</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqFjk9LwzAYxoMgbujunuT9Aq1J3masV8eGHgYFBY8jW7P2lSYtSVo2z35we7Cwm6cHfs8fHsYeBU8RV_nziaztU8klTznncnXD5mK5zBKUMpuxRQhfI-ZZjojqjs1QCoVKqTn7KXwbzTHSYOBt3HAUL0AOdnScwLcp4ZNiDUUKAw36DLv3QoDIIXnRYTS3rbd9oyO1LoB2Jaxr3TTGVVfFg_FVbQg2586bEMhVUAzT0AO7PekmmMWf3rOn7eZj_Zp0_cGact95stpf9tNt_DfwC2j6Upc</recordid><startdate>2020</startdate><enddate>2020</enddate><creator>Dobrescu, Irina</creator><creator>de Camargo, Tarsila Mendes</creator><creator>Gimenez, Alba Marina</creator><creator>Murillo, Oscar</creator><creator>Amorim, Kelly Nazaré da Silva</creator><creator>Marinho, Claudio Romero Farias</creator><creator>Soares, Irene Silva</creator><creator>Boscardin, Silvia Beatriz</creator><creator>Bargieri, Daniel Youssef</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>2020</creationdate><title>Protective Immunity in Mice Immunized With P. vivax MSP1 19 -Based Formulations and Challenged With P. berghei Expressing Pv MSP1 19</title><author>Dobrescu, Irina ; de Camargo, Tarsila Mendes ; Gimenez, Alba Marina ; Murillo, Oscar ; Amorim, Kelly Nazaré da Silva ; Marinho, Claudio Romero Farias ; Soares, Irene Silva ; Boscardin, Silvia Beatriz ; Bargieri, Daniel Youssef</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_321535553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Antibodies, Protozoan - immunology</topic><topic>Antigens, Protozoan - immunology</topic><topic>Female</topic><topic>Immunogenicity, Vaccine</topic><topic>Malaria Vaccines - immunology</topic><topic>Malaria, Vivax - immunology</topic><topic>Malaria, Vivax - parasitology</topic><topic>Merozoite Surface Protein 1 - immunology</topic><topic>Merozoite Surface Protein 1 - metabolism</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Mice, Inbred C57BL</topic><topic>Parasitemia - immunology</topic><topic>Plasmids - genetics</topic><topic>Plasmodium berghei - genetics</topic><topic>Plasmodium berghei - metabolism</topic><topic>Plasmodium vivax - immunology</topic><topic>Protozoan Proteins - immunology</topic><topic>Transfection</topic><topic>Treatment Outcome</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dobrescu, Irina</creatorcontrib><creatorcontrib>de Camargo, Tarsila Mendes</creatorcontrib><creatorcontrib>Gimenez, Alba Marina</creatorcontrib><creatorcontrib>Murillo, Oscar</creatorcontrib><creatorcontrib>Amorim, Kelly Nazaré da Silva</creatorcontrib><creatorcontrib>Marinho, Claudio Romero Farias</creatorcontrib><creatorcontrib>Soares, Irene Silva</creatorcontrib><creatorcontrib>Boscardin, Silvia Beatriz</creatorcontrib><creatorcontrib>Bargieri, Daniel Youssef</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Frontiers in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dobrescu, Irina</au><au>de Camargo, Tarsila Mendes</au><au>Gimenez, Alba Marina</au><au>Murillo, Oscar</au><au>Amorim, Kelly Nazaré da Silva</au><au>Marinho, Claudio Romero Farias</au><au>Soares, Irene Silva</au><au>Boscardin, Silvia Beatriz</au><au>Bargieri, Daniel Youssef</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Protective Immunity in Mice Immunized With P. vivax MSP1 19 -Based Formulations and Challenged With P. berghei Expressing Pv MSP1 19</atitle><jtitle>Frontiers in immunology</jtitle><addtitle>Front Immunol</addtitle><date>2020</date><risdate>2020</risdate><volume>11</volume><spage>28</spage><pages>28-</pages><eissn>1664-3224</eissn><abstract>The lack of continuous cultures has been an obstacle delaying pre-clinical testing of vaccine formulations based on known antigens. In this study, we generated a model to test available formulations based on the MSP1 antigen. The strains ANKA and NK65 were modified to express MSP1 instead of the endogenous MSP1 . The hybrid parasites were used to challenge C57BL/6 or BALB/c mice immunized with MSP1 -based vaccine formulations. The MSP1 was correctly expressed in the hybrid mutant lines as confirmed by immunofluorescence using anti- MSP1 monoclonal antibodies and by Western blot. Replacement of the MSP1 by the MSP1 had no impact on asexual growth . High titers of specific antibodies to MSP1 were not sufficient to control initial parasitemia in the immunized mice, but late parasitemia control and a balanced inflammatory process protected these mice from dying, suggesting that an established immune response to MSP1 in this model can help immunity mounted later during infection.</abstract><cop>Switzerland</cop><pmid>32153555</pmid><doi>10.3389/fimmu.2020.00028</doi></addata></record>
fulltext	fulltext
identifier	EISSN: 1664-3224
ispartof	Frontiers in immunology, 2020, Vol.11, p.28
issn	1664-3224
language	eng
recordid	cdi_pubmed_primary_32153555
source	PubMed Central
subjects	Animals Antibodies, Protozoan - immunology Antigens, Protozoan - immunology Female Immunogenicity, Vaccine Malaria Vaccines - immunology Malaria, Vivax - immunology Malaria, Vivax - parasitology Merozoite Surface Protein 1 - immunology Merozoite Surface Protein 1 - metabolism Mice Mice, Inbred BALB C Mice, Inbred C57BL Parasitemia - immunology Plasmids - genetics Plasmodium berghei - genetics Plasmodium berghei - metabolism Plasmodium vivax - immunology Protozoan Proteins - immunology Transfection Treatment Outcome Vaccination
title	Protective Immunity in Mice Immunized With P. vivax MSP1 19 -Based Formulations and Challenged With P. berghei Expressing Pv MSP1 19
url	http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T01%3A30%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Protective%20Immunity%20in%20Mice%20Immunized%20With%20P.%20vivax%20MSP1%2019%20-Based%20Formulations%20and%20Challenged%20With%20P.%20berghei%20Expressing%20Pv%20MSP1%2019&rft.jtitle=Frontiers%20in%20immunology&rft.au=Dobrescu,%20Irina&rft.date=2020&rft.volume=11&rft.spage=28&rft.pages=28-&rft.eissn=1664-3224&rft_id=info:doi/10.3389/fimmu.2020.00028&rft_dat=%3Cpubmed%3E32153555%3C/pubmed%3E%3Cgrp_id%3Ecdi_FETCH-pubmed_primary_321535553%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/32153555&rfr_iscdi=true